3D-descriptors in modeling the dipeptidyl peptidase IV (DPP-4) inhibition activity: Derivatives of β-Aminoamide bearing subsituted triazolopiperazines
DOI:
https://doi.org/10.56511/JIPBS.2020.v7.i03.pp39-53Abstract
The DPP-4 and DPP-8 inhibitory activity of triazolopiperazines have been quantitatively analyzed in terms of 3D-Dragon descriptors. The derived QSAR models have shown that atomic properties played pivotal role in terms of weighted radial distribution functions, 3D-MoRSE signals, component symmetry directional WHIM index and moment expansions. The CP-MLR indentified RDF, 3D-MoRSE, WHIM and GETAWAY descriptors, unweighted or weighted with atomic properties endow relevant molecular 3D informations about molecular size, shape, symmetry, atom distribution, effective position of substituents and fragments in the molecular space, hold promise for rationalizing the DPP-4 and DPP-8 inhibitory actions of triazolopiperazines. The values of statistical parameters, Q2LOO and r2Test ensure that the models have validated internally and externally, both and the predictions are reliable and acceptable. PLS analysis has further confirmed the dominance of the CP‐MLR identified descriptors. Applicability domain analysis revealed that the suggested models have acceptable predictability. All the compounds are within the applicability domain of the proposed models and were evaluated correctly
Keywords:
QSAR, DPP-4 and DPP-8 inhibitors, Combinatorial protocol in multiple linear regression (CP-MLR) analysis, 3D-Dragon descriptors, TriazolopiperazinesDownloads
References
King, H.; Aubert, R. E. and Herman, W. H. Global burden of diabetes, 1995 – 2025: Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414 – 1431.
Wagman, A. S. and Nuss, J. M. Current therapies and emerging targets for the treatment of diabetes. Current Pharmaceutical Design 2001; 7: 417 – 450.
Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Journal of Medicinal Chemistry 2004; 47: 4135 – 4141.
Augustyns, K.; der Veken, P. V.; Senten, K. and Haemers, A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP-4) and related proline-specific dipeptidyl aminopeptidases. Current Medicinal Chemistry 2005; 12: 971 – 998.
Augustyns, K.; der Veken, P. V. and Haemers, A. Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as novel approach for the treatment of type 2 diabetes. Expert Opinion on Therapeutic Patents 2005; 15: 1387 – 1407.
von Geldern, T. W. and Trevillyan, J. M. “The next big thing” in diabetes: Clinical progress on DPP-IV inhibitors. Drug Development Research 2006; 67: 627 – 642.
Orsakov, C. Glucagon-like peptide 1, a new hormone of the enteroinsular axis. Diabetologia 1992; 35: 701 – 711.
Zander, M.; Madsbad, S.; Madsen, J. L. and Holst, J. J. Effect of 6week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and -cell function in type 2 diabetes; a parallel-group study. Lancet 2002; 359: 824 – 830.
Knudsen, L. B. Glucagon-like peptide 1: A basis of a new class of treatment for type 2 diabetes. Journal of Medicinal Chemistry 2004; 47: 4128 – 4134.
Vahl, T. P. and D’Alessio, D. A. Gut peptides in the treatment of diabetes mellitus. Expert Opinion on Investigational Drugs 2004; 13: 177 – 188.
Meier, J. J and Nauck, M. A. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metabolism Research and Reviews 2005; 21: 91 – 117.
Drucker, D. J. and Nauck, M. A. The inceretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696 – 1705.
Combettes, M. M. J. GLP-1 and type 2 diabetes: physiology and new clinical advances. Current Opinion in Pharmacology 2006; 6: 598 – 605.
Wettergren, A.; Schjoldager, B.; Martensen, P. E.; Myhre, J.; Christiansen, J. and Holst, J. J. Truncated GLP-1 (proglucagon 72 – 107 amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences 1993; 38: 665 – 673.
Nauck, M. A,; Niedereichholz, U.; Ettler, R.; Holst, J. J.; Orskov, C.; Ritzel, R. and Schmigel, W. H. Glucagon-like peptide-1 inhibition of gastric-emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology 1997; 273: E981 – E988.
Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J. J. and Astrup, A. The effect of physiological levels of glucagons-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity 2001; 25: 781 – 792.
Ahren, B. E. Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discovery Today 2004; 1: 207 – 212.
Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004; 53: 2181 – 2189.
Deacon, C. F. and Holst, J. J. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacolology 2004; 4: 589 – 596.
Mentlein, R. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opinion on Investigational Drugs 2005; 14: 57 – 64.
Nielsen, L. L. Incretin mimetics and DPP-4 Inhibitors for the treatment of type 2 diabetes. Drug Discovery Today 2005; 10: 703 – 710.
Gautier, J. F.; Fetita, S.; Sobngwi, E. and Salaun-Martin, C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes and Metabolism 2005; 31: 233 – 242.
Kieffer, T. J.; McIntosh, C. H. S. and Pederson, T. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagonlike peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585 – 3596.
Deacon, C. F.; Nauck, M. A.; Toft-Nielson, M.; Pridal, L.; Willms, B. and Holst, J. J. Both subcutaneously and intravenously administered glucagons-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126 – 1131.
Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Sinha Roy, R.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A. and Weber, A. E. (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 2005; 48: 141 – 151.
Edmondson, S. E.; Fisher, M. H.; Kim, D.; Maccoss, M.; Parmee, E. R.; Weber, A. E. and Xu, J. U. S. Patent 6,699,871 B2, Mar. 2, 2004.
Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E. and Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S)-pyrrolidine: A potent selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medicinal Chemistry 2003; 46: 2774 – 2789.
Magnin, D. R.; Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Huang, Y.; Simpkins, L. M.; Taunk, P. C.; Betebenner, D. A.; Robertson, J. G.; Abboa-Offei, B. E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D. F.; Malley, M. F.; Gougoutas, J. Z.; Khanna, A.; Huang, Q.; Han, S.; Parker, R. A. and Hamann, L. G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: Interplay between the Nterminal amino acid alkyl side chain and the cyclopropyl group of -aminoacyl-l-cis-4,5methanoprolinenitrile based inhibitors. Journal of Medicinal Chemistry 2004; 47: 2587-2598.
Kim, D.; Kowalchick, J. E.; Edmondson, S. D.; Mastracchio, A.; Xu, J. M.; Eiermann, G. J.; Leiting, B.; Wu, J. K.; Pryor, K.; Patel, R. A.; He, H.; Lyons, K. A.; Thornberry N. A. and Weber, A. E. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogues of JANUVIATM (sitagliptin phosphate). Bioorganic and Medicinal Chemistry Letters 2007; 17: 3373-3377.
Xu, J.; Ok, H. O.; Gonzalez, E. J.; Colwell, L. F. Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyona, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. and Parmee, E. R. Discovery of potent and selective -Homophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters 2004; 14: 4759 – 4762.
Brockunier, L.; He, J.; Colwell, L. F. Jr.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R.; Teffera, Y.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. and Parmee, E. R. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters 2004; 14: 4763 – 4766.
Kim, D.; Kowalchick, J. E.; Brockunier, L. L.; Parmee, E. R.; Eiermann, G. J.; Fisher, M. H.; He, H.; Leiting, B.; Lyons, K.; Scapin, G.; Patel, S. B.; Petrov, A.; Pryor, K. D.; Roy, R. S.; Wu, J. K.; Zhang, X.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. and Weber, A. E. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from -Aminoamides bearing subsituted triazolopiperazines. Journal of Medicinal Chemistry 2008; 51: 589 – 602.
Chemdraw ultra 6.0 and Chem3D ultra, Cambridge Soft Corporation, Cambridge, USA.
Dragon software (version 1.11-2001) by Todeschini R.; Consonni V. Milano, Italy.
Prabhakar, Y. S. A combinatorial approach to the variable selection in multiple linear regression: Analysis of Selwood et al. Data Set-a case study. QSAR and Combinatorial Science 2003; 22: 583-595.
Sharma, S.; Prabhakar, Y. S.; Singh, P. and Sharma, B. K. QSAR study about ATP-sensitive potassium channel activation of cromakalim analogues using CP-MLR approach. European Journal of Medicinal Chemistry 2008; 43: 2354-2360.
Sharma, S.; Sharma, B. K.; Sharma, S. K.; Singh, P. and Prabhakar, Y. S. Topological descriptors in modeling the agonistic activity of human A3 adenosine receptor ligands: The derivatives of 2-Chloro-N6substituted-4'-thioadenosine-5'-uronamide, European Journal of Medicinal Chemistry 2009; 44: 1377-1382.
Sharma, B. K.; Pilania, P.; Singh, P. and Prabhakar, Y. S. Combinatorial protocol in multiple linear regression/partial leastsquares directed rationale for the caspase-3 inhibition activity of isoquinoline-1,3,4-trione derivatives. SAR QSAR in Environmental Research 2010; 21: 169-185.
Sharma, B. K.; Singh, P.; Sarbhai, K. and Prabhakar, Y. S. A quantitative structureactivity relationship study on serotonin 5-HT6 receptor ligands: Indolyl and piperidinyl sulphonamides, SAR QSAR in Environmental Research 2010; 21: 369-388.
Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978; 20: 397 – 405.
Kettaneh, N.; Berglund, A. and Wold, S. PCA and PLS with very large data sets. Computational Statistics and Data Analysis 2005; 48: 69 – 85.
Stahle, L. and Wold, S. Multivariate data analysis and experimental design. In: Ellis, G. P. and West, W. B. (Eds.), Biomedical research. Progress in medicinal chemistry. Elsevier Science Publishers, BV, Amsterdam.1988; 25: 291 – 338.
Topliss, J. G. and Edwards, R. P. Chance factors in studies of quantitative structure – activity relationships. Journal of Medicinal Chemistry 1979; 22: 1238 – 1244.
Katritzky, A. R.; Dobchev, D. A.; Slavov, S. and Karelson M. Legitimate utilization of large descriptor pools for QSAR/QSPR models. Journal of Chemical Information and Modeling 2008; 48: 2207 – 2213.
So, S. – S. and Karplus, M. Three-dimensional quantitative structure – activity relationship from molecular similarity matrices and genetic neural networks. 1. Method and validation. Journal of Medicinal Chemistry 1997; 40: 4347 – 4359.
Prabhakar, Y. S.; Solomon, V. R.; Rawal, R. K.; Gupta, M. K. and Katti, S. B. CP-MLR/ PLS directed structure – activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR and Combinatorial Science 2004; 23: 234 – 244.
Akaike, H. Information theory and an extension of the minimum likelihood principle. In: Petrov, B. N. and Csaki, F. (Eds.). Second international symposium on information theory. Budapest: Akademiai Kiado; 1973. p 267 – 281.
Akaike, H. A new look at the statistical identification model. IEEE Transactions on Automatic Control 1974; AC-19: 716 – 723.
Kubinyi, H. Variable selection in QSAR studies. I. An evolutionary algorithm. Quantitative Structure-Activity Relationship 1994; 13: 285 – 294.
Kubinyi, H. Variable selection in QSAR studies. II. A highly efficient combination of systematic search and evolution. Quantitative Structure-Activity Relationship 1994; 13:393 – 401.
Friedman J. In Technical Report No. 102. Laboratory for Computational Statistics, Stanford University: Stanford; 1990.
Gramatica, P. Principles of QSAR models validation: internal and external. QSAR and Combinatorial Science 2007; 26: 694-701.
Hemmer, M. C.; Steinhauer, V. and Gasteiger, J. Deriving the 3D structure of organic molecules from their infrared spectra. Vibrational Spectroscopy 1999; 19: 151-164.
Silverman, B. D. Three-dimensional moments of molecular property fields. The Journal for Chemical Information and Computer Scientists 2000; 40: 1470-1476.
Schuur, J. H.; Selzer, P. and Gasteiger, J. The Coding of the threedimensional structure of molecules by molecular transforms and its application to structure-spectra correlations and studies of biological activity. Journal of the American Chemical Society 1996; 36: 334-344.
(a) Consonni, V.; Todeschini, R. and Pavan, M. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. The Journal for Chemical Information and Computer Scientists 2002; 42: 682-692. (b) Consonni, V.; Todeschini, R.; Pavan, M. and Gramatica, P. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 2. Application of the novel 3D molecular descriptors to QSAR/QSPR studies. The Journal for Chemical Information and Computer Scientists 2002; 42: 693705.
(a) Todeschini, R.; Lasagni, M. and Marengo, E. New molecular descriptors for 2D and 3D structures. Theory. Journal of Chemometrics 1994; 8: 263-273. (b) Todeschini, R. and Gramatica, P. 3D QSAR in drug design - vol. 2, Kubinyi, H.; Folkers, G. and Martin, Y. C. (Eds.), Kluwer/ESCOM, Dordrecht (The Netherlands), 1998; 355-380.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Raghuraj Parihar, Afsar Jahan, Brij Kishore Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at